Search

Displaying results 3751 - 3760 of 7018 in total
  1. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma. … RGN6024, also known as RGN-6024 or RGNi6024, is a synthetic small-molecule tubulin destabilizer from Reglagene.

  2. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

  3. Drug

    Ziconotide

    go.drugbank.com/drugs/DB06283
    ApprovedInvestigational

    Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds. … [A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Pentamidine

    go.drugbank.com/drugs/DB00738
    ApprovedInvestigational

    It may cause diabetes mellitus, central nervous system damage, and other toxic effects.

  5. Drug

    Dapoxetine

    go.drugbank.com/drugs/DB04884
    Investigational

    In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions. … In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo.

  6. Drug

    Ketazolam

    go.drugbank.com/drugs/DB01587
    ApprovedWithdrawn

    Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.

  7. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    [L4563] Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation. … that the drug, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition.

  8. Drug

    Lutropin alfa

    go.drugbank.com/drugs/DB00044
    ApprovedInvestigational

    Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein made up of monomeric units. … Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum.

  9. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive … It was first approved by the FDA on August 27, 2018 [L4540].

    Categories: Monoamine Oxidase A Substrates
  10. Drug

    p-Fluorofentanyl

    go.drugbank.com/drugs/DB09177
    ExperimentalIllicit

    p-Fluorofentanyl is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s. p-Fluorofentanyl was sold briefly on the US black market in the early 1980s, before … the introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as